Will Harrow stock go up?

According to Danelfin AI, Harrow has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (55.52%) is +4.70% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Harrow stock?

The Harrow target price is $69.28 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Harrow stock right now?

Harrow has today a Hold rating (AI Score 6/10), according to Danelfin AI. Its probability of beating the market in 3 months (55.52%) is +4.70% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Harrow stock is a good buy .

Is Harrow undervalued right now?

Based on analysts, the average price target upside for Harrow is +61.04% (1Y). According to Danelfin AI, Harrow has today an AI Score of 6/10 (Hold Rating).

What was the price range of Harrow stock over the past 12 months?

The Harrow stock price range over the past 12 months has been $29.03 - $54.8.

What is going on with Harrow stock in the last 3 months?

The Harrow stock performance in the last quarter has been +22.00%.

Does Harrow offer dividend payments?

No, Harrow does not currently pay dividends.

What is the current market capitalization of Harrow?

Harrow's market cap is $1.6B, as of 2026-07-02 08:00.

When is the next HROW earnings report date?

HROW will publish its next earnings report on 2026-05-11.

Harrow Inc (HROW) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

HROW AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Harrow Inc today receives an AI Score of 6/10, which translates to a Hold rating. The stock has a 56% probability of outperforming the market in the next 3 months, which is 5% higher than the average probability of any stock (51%). This modestly elevated probability is driven by several positive contributors. The most impactful is its classification in the Pharmaceuticals industry, which adds +2.32% to the probability. The aggregated long tail of fundamental signals also provides a significant boost of +2.19%. However, these positives are partially offset by detractors. The current Fear & Greed Index reading of 31 (indicating fear) detracts -0.93%, and a negative Chart Pattern (60d) weighs down the probability by -0.91%. Notable data points that help explain this probability include a very weak Operating Cash Flow for the most recent quarter and an Operating Profit Margin of -49.95%, both ranking in the bottom 20% of the market, which are significant negative fundamentals. On a positive note, Institutional Ownership is 57.81%, placing it in the top 50%, which indicates professional investor confidence. The stock's ATR (14d Volatility) is relatively high, ranking in the top 30%, signaling greater price risk. Overall, while the stock's industry and aggregated signals provide a probability edge, its poor recent profitability and cash generation, combined with cautious market sentiment, temper the outlook, resulting in a Hold rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Sentiment+2.30%
How analysts and the market view the stock
Valuation+1.43%
How the stock is priced relative to its fundamentals
Earnings Quality+1.34%
Stability and reliability of reported earnings
Momentum+0.37%
Direction and strength of recent price movements
Size & Liquidity+0.36%
Company size and trading liquidity

Profitability-0.57%
Profitability and operating efficiency metrics
Volatility-0.53%
How much the stock price tends to fluctuate

HROW probability advantage of beating the market (3M):

+4.70%

AI Score

Hold

Harrow (HROW) has an AI Score of 6/10 (Hold) because, according to an overall analysis, it has a probability advantage of +4.70% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of HROW (55.52%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
HROW probability advantage of beating the market (3M)+4.70%
HROW probability of beating the market (3M)55.52%

HROW probability advantage of beating the market (3M): +4.70%

The AI-powered overall analysis of Harrow (HROW) is based on the 25 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of HROW:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Pharmaceuticals	N/A	+2.32%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+2.19%
Fundamental	Operating Cash Flow (Qtr Discrete)	-8.99		+1.34%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.93%
Technical	Chart Pattern (60d)	figure_192	N/A	-0.91%
Sentiment	Earnings Countdown	-46		+0.60%
Fundamental	Operating Profit Margin	-49.95%		-0.57%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.54%
Technical	ATR (14d Volatility)	2.03		-0.53%
Sentiment	Institutional Ownership	57.81%		+0.38%
Fundamental	Upgrade to unlock			-0.38%
Technical	Upgrade to unlock			+0.38%
Fundamental	Upgrade to unlock			-0.37%
Fundamental	Upgrade to unlock			+0.36%
Technical	Upgrade to unlock			-0.31%

Rest of Alpha Signals: +1.29%

HROW probability advantage of beating the market (3M)Total:+4.70%
HROW AI Score

Significant changes Vs previous day

HROW Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$43.02
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

HROW Proven Hold Signal & Price Forecast

This is the price chart for HROW from January 1, 2026 until today. The chart indicates, in yellow, the 51 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

HROW Average Past Performance & Win Rate

Three months after its 1494 Hold signals since July 2026, HROW had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

1494 Past HROW Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+61.23%
Average Alpha				+45.46%
Win Rate (% Positive Perf.)				68.85%
% Positive Alpha				57.55%

HROW Frequently Asked Questions

Will Harrow stock go up?
According to Danelfin AI, Harrow has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (55.52%) is +4.70% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Harrow stock?
Is it a good time to buy, sell, or hold Harrow stock right now?
Is Harrow undervalued right now?
What was the price range of Harrow stock over the past 12 months?
What is going on with Harrow stock in the last 3 months?
Does Harrow offer dividend payments?
What is the current market capitalization of Harrow?
When is the next HROW earnings report date?

Harrow Inc Company Profile

Harrow, Inc., a pharmacy enterprise with a concentration in eye health care, is involved in uncovering, cultivating and introducing ocular pharmaceutical commodities into the market. One of its offerings is called ImprimisRx, a treatment specifically developed to serve ophthalmology requirements. Harrow also brings forth IHEEZO - an ophthalmic gel comprised of chloroprocaine hydrochloride; as well as a variety of ophthalmic solutions like IOPIDINE, VEVYE and ZERVIATE.

Additionally, it provides MAXITROL, beneficial eye drops; along with ILEVRO and NEVANAC being non-steroidal and anti-inflammatory eye drops designed for the management of discomfort and inflammation linked to cataract surgeries. The company's other production line features FLAREX and MAXIDEX - these are steroid-based eye-drops targeting steroid-responsive inflammation arising within the palpebral and bulbar conjunctiva regions as well as cornea and anterior segment of the globe or eyesight space.

Harrow's portfolio extends further to include TRIESENCE - injectable steroids serving dual purposes: treating various ocular diseases on one hand while enhancing visualization during vitrectomy procedures on others. Rounding out this collection is NATACYN - an antifungal medical solution dealing specifically with fungal infections such as blepharitis, conjunctivitis, keratitis among others.

Moreover, the firm offers TOBRADEX ST – an amalgamated suspension of tobramycin plus dexamethasone; VERKAZIA – which is an emulsion based on the active compound cyclosporine; again featuring NEVANAC – another non-steroidal drop catering to eye inflammation after surgeries but bearing additional compounds; eventually ending FRESHKOTE Preservative Free (PF) series maintaining the composition similar to natural tears ensuring lubricating effects when applied over strained eyes.

Initially, Harrow, Inc. was recognized as Harrow Health, Inc., but then underwent a company name change in September 2023. Hailing from its establishment dated back to 1998, the corporate headquarters now sits in Nashville, Tennessee.

Sector:Health Care
Country:United States
Industry:Pharmaceuticals
Address:1A Burton Hills Blvd, Suite 200, Nashville
Employees:373
Website:harrow.com

Pros

Niche market focus in ophthalmic pharmaceuticals

Growth via acquisition of established ophthalmic assets

Specialized distribution network for eye care products

Patient and prescriber inertia for chronic ophthalmic therapies

Demographic tailwinds from an aging global population

Cons

Integration risk of acquired pharmaceutical product portfolios

Pros

Cons

Company	AI Score	Compare
OCULOcular Therapeutix Inc

Company

AI Score

Compare

OCULOcular Therapeutix Inc

Company

AI Score

Compare

HROW Top 10 Industry Stocks

Pharmaceuticals

	Company	AI Score	Compare
1	LBRXLB Pharmaceuticals Inc
2	PAHCPhibro Animal Health Corp
3	EYPTEyePoint Inc
4	JAZZJazz Pharmaceuticals PLC
5	GSKGSK plc
6	RAPPRapport Therapeutics Inc
7	PHVSPharvaris NV
8	LENZLENZ Therapeutics Inc
9	MAZEMaze Therapeutics Inc
10	TARSTarsus Pharmaceuticals Inc

	Company	AI Score	Compare

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc

Company

AI Score

Compare

COGTCogent Biosciences Inc

Company

AI Score

Compare

HROW Stock AI Analysis

Harrow Inc

HROW Stock AI Analysis

Harrow Inc

HROW AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

HROW probability advantage of beating the market (3M): +4.70%

HROW Trading Parameters

HROW Proven Hold Signal & Price Forecast

HROW Average Past Performance & Win Rate

HROW Frequently Asked Questions

Will Harrow stock go up?

What is the target price for Harrow stock?

Is it a good time to buy, sell, or hold Harrow stock right now?

Is Harrow undervalued right now?

What was the price range of Harrow stock over the past 12 months?

What is going on with Harrow stock in the last 3 months?

Does Harrow offer dividend payments?

What is the current market capitalization of Harrow?

When is the next HROW earnings report date?

Harrow Inc Company Profile

Pros

Cons

Pros

Cons

HROW Company Profile Summary

HROW Related Investment Themes

HROW Related Stocks

HROW Top 10 Industry Stocks

Pharmaceuticals

HROW Top 10 Sector Stocks

Health Care

HROW Stock AI Analysis

Harrow Inc

NASDAQ NMS - GLOBAL MARKET

Will Harrow stock go up?

What is the target price for Harrow stock?

Is it a good time to buy, sell, or hold Harrow stock right now?

Is Harrow undervalued right now?

What was the price range of Harrow stock over the past 12 months?

What is going on with Harrow stock in the last 3 months?

Does Harrow offer dividend payments?

What is the current market capitalization of Harrow?

When is the next HROW earnings report date?

Pros

Cons

NASDAQ NMS - GLOBAL MARKET

AI Score Explanation

HROW Proven Hold Signal & Price Forecast